PRXL2B

Across TCGA pan-cancer cohorts, PRXL2B RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated PRXL2B data layer compared with 4 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher PRXL2B RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated PRXL2B expression acts as an unfavorable survival marker, although some lineages such as UVM and DLBC show a favorable association.

UVM, ACC, and LIHC are the cancer types where PRXL2B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Tertile	All	0.784	0.389	<.001	72	view →
ACC	DFS	Tertile	II,III,IV	0.290	0.662	.001	60	view →
LIHC	OS	Median	II,III,IV	0.491	0.734	<.001	59	view →
DLBC	DFS	Median	IV	1.000	0.281	.005	53	view →
KIRC	DFS	Median	All	0.727	0.520	<.001	48	view →
MESO	OS	Median	All	0.513	0.295	.002	42	view →
SKCM	OS	Quartile	All	0.699	0.857	<.001	39	view →
LGG	OS	Median	All	0.757	0.868	<.001	38	view →
STAD	OS	Tertile	All	0.759	0.627	.014	31	view →
THCA	DFS	Median	II,III,IV	0.520	0.811	.002	28	view →
BRCA	DFS	Tertile	IV	0.869	0.308	.005	25	view →
CHOL	DFS	Quartile	II,III,IV	0.792	0.093	.004	23	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

PRXL2B–UVM (DFS)

Open the UVM breakdown →